PD-1 and PD-L1 antibodies in cancer: current status and future directions

AV Balar, JS Weber - Cancer Immunology, Immunotherapy, 2017 - Springer
Immunotherapy has moved to the center stage of cancer treatment with the recent success of
trials in solid tumors with PD-1/PD-L1 axis blockade. Programmed death-1 or PD-1 is a …
被引用次数：318 相关文章

PD-1 and PD-L1 antibodies in cancer: current status and future directions

AV Balar, JS Weber - Cancer Immunology, Immunotherapy, 2017 - search.proquest.com
Immunotherapy has moved to the center stage of cancer treatment with the recent success of
trials in solid tumors with PD-1/PD-L1 axis blockade. Programmed death-1 or PD-1 is a …

[引用][C] PD-1 and PD-L1 antibodies in cancer: current status and future directions

AV Balar, JS Weber - Cancer Immunology, Immunotherapy, 2017 - cir.nii.ac.jp
PD-1 and PD-L1 antibodies in cancer: current status and future directions | CiNii Research
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …

PD-1 and PD-L1 antibodies in cancer: current status and future directions.

A Balar, J Weber - Cancer Immunology, Immunotherapy, 2017 - search.ebscohost.com
Immunotherapy has moved to the center stage of cancer treatment with the recent success of
trials in solid tumors with PD-1/PD-L1 axis blockade. Programmed death-1 or PD-1 is a …

PD-1 and PD-L1 antibodies in cancer: current status and future directions

AV Balar, JS Weber - Cancer Immunology, Immunotherapy, 2017 - infona.pl
Immunotherapy has moved to the center stage of cancer treatment with the recent success of
trials in solid tumors with PD-1/PD-L1 axis blockade. Programmed death-1 or PD-1 is a …

PD-1 and PD-L1 antibodies in cancer: current status and future directions.

AV Balar, JS Weber - Cancer Immunology, Immunotherapy: CII, 2017 - europepmc.org
Immunotherapy has moved to the center stage of cancer treatment with the recent success of
trials in solid tumors with PD-1/PD-L1 axis blockade. Programmed death-1 or PD-1 is a …

PD-1 and PD-L1 antibodies in cancer: current status and future directions

AV Balar, JS Weber - … immunology, immunotherapy: CII, 2017 - pubmed.ncbi.nlm.nih.gov
Immunotherapy has moved to the center stage of cancer treatment with the recent success of
trials in solid tumors with PD-1/PD-L1 axis blockade. Programmed death-1 or PD-1 is a …

[引用][C] PD-1 and PD-L1 antibodies in cancer: current status and future directions

AV Balar, JS Weber - Cancer immunology, immunotherapy, 2017 - Springer